December 16, 2016 | by City of Hope
Cancer in the bloodstream can be just as aggressive as cancers that form solid masses.
Fortunately, the long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease and multiple myeloma.
Here with thoughts on what City of Hope offers your patients is Steven T. Rosen, M.D., provost and chief scientific officer.
You may also be interested in